Cannabinoid Medication for Adults With OCD
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 1/23/2019 |
| Start Date: | September 2016 |
| End Date: | January 2019 |
Cannabinoid Medication for Adults With Obsessive-Compulsive Disorder (OCD)
The purpose of this pilot research study is to test the effects of a medication called
nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will
receive either nabilone on its own, or nabilone in combination with a form of
cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone
is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been
hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of
chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.
nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will
receive either nabilone on its own, or nabilone in combination with a form of
cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone
is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been
hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of
chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.
Inclusion Criteria:
- Age 18-60
- Physically healthy, not pregnant
- Primary OCD
- Patient off all psychotropic (except selective SRIs) and other types of drugs likely
to interact with nabilone
- Ability to provide informed consent
- Ability to tolerate a treatment free-period
Exclusion Criteria:
- History of any significant medical condition that may increase the risk of
participation
- Females who are pregnant or nursing
- Current or lifetime history of psychiatric disorders other than OCD that may increase
the risk of participation (e.g. lifetime psychosis or bipolar disorder)
- Current substance use disorder or positive urine toxicology at screening, or any
adverse reaction to a cannabinoid
- Patients already receiving EX/RP
We found this trial at
1
site
1051 Riverside Dr
New York, New York 10032
New York, New York 10032
646-774-5000
Phone: 646-774-8138
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
Click here to add this to my saved trials
